Defining Unmet Need to Optimize Management of Adults and Adolescents With Psoriasis: Development of a Global Multistakeholder Survey
Moderator
Guo Li, MBA, Johnson and Johnson Innovative Medicine (JJIM), Raritan, NJ, United States
Speakers
Laurie Conklin, MD; Gale Harding; Kimberly Bailey, MSc, Evidera, PCR, Wilmington, NC, United States; Ashley Duenas, MSc; Timothy Patrick Fitzgerald, PhD, BS, MA; Melina Taylor; Oluwakayode Adejoro, MD, Janssen, Horsham, PA, United States; Rebecca Padula; Ya-Wen Yang
OBJECTIVES: Perspectives of patients and health care providers (HCPs) are critical to define unmet need in the treatment of psoriasis, and these perspectives may be different. Furthermore, views of adolescents with psoriasis may differ from their parents, or from adults with psoriasis. To address these questions, a targeted literature review was conducted to inform survey development eliciting insights from adults and adolescents with psoriasis, caregivers of adolescents with psoriasis, and HCPs who treat them.
METHODS: A stepwise approach was undertaken to identify themes and form the basis of the survey: 1) a targeted literature review of studies focused on patient/clinician perceptions of unmet treatment needs or patient preferences; 2) a Steering Committee comprised of 3 patient partners and 8 HCPs to provide clinical and patient-centric guidance on the study design, execution and results dissemination; and 3) survey pilot testing among adult patients, adolescent patients/caregivers, and HCPs (n=15 total) in the US.
RESULTS: Key concepts identified from the literature review for both adults and adolescents included treatment safety, efficacy, mode of administration, and insurance coverage. Loss of efficacy was most important to adults, while underutilization of systemic treatment and convenience were key concepts for adolescents. The Steering Committee identified other key concepts, including factors influencing treatment selection, treatment goals, and treatment experience. The survey pilot showed that participants understood the questions and response options. It also highlighted the need to add questions regarding location of symptoms, seasonality, treatment side-effects, and social and emotional aspects of psoriasis.
CONCLUSIONS: Next steps in study development involve a mixed-method approach, combining quantitative survey and qualitative interviews to characterize treatment experience, and perceptions of PsO treatments. The study includes participants from diverse regions globally, with surveys and interviews conducted among adolescent and adult PsO patients, caregivers and HCPs.
METHODS: A stepwise approach was undertaken to identify themes and form the basis of the survey: 1) a targeted literature review of studies focused on patient/clinician perceptions of unmet treatment needs or patient preferences; 2) a Steering Committee comprised of 3 patient partners and 8 HCPs to provide clinical and patient-centric guidance on the study design, execution and results dissemination; and 3) survey pilot testing among adult patients, adolescent patients/caregivers, and HCPs (n=15 total) in the US.
RESULTS: Key concepts identified from the literature review for both adults and adolescents included treatment safety, efficacy, mode of administration, and insurance coverage. Loss of efficacy was most important to adults, while underutilization of systemic treatment and convenience were key concepts for adolescents. The Steering Committee identified other key concepts, including factors influencing treatment selection, treatment goals, and treatment experience. The survey pilot showed that participants understood the questions and response options. It also highlighted the need to add questions regarding location of symptoms, seasonality, treatment side-effects, and social and emotional aspects of psoriasis.
CONCLUSIONS: Next steps in study development involve a mixed-method approach, combining quantitative survey and qualitative interviews to characterize treatment experience, and perceptions of PsO treatments. The study includes participants from diverse regions globally, with surveys and interviews conducted among adolescent and adult PsO patients, caregivers and HCPs.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
PCR26
Topic
Patient-Centered Research
Topic Subcategory
Patient Engagement, Patient-reported Outcomes & Quality of Life Outcomes
Disease
SDC: Sensory System Disorders (Ear, Eye, Dental, Skin), STA: Biologics & Biosimilars, STA: Multiple/Other Specialized Treatments